An update on proteinuric chronic kidney disease: the dual-goal approach.
Lowering both blood pressure and urinary albumin excretion to specific goals may slow the progression of proteinuric chronic kidney disease. However, this dual-goal approach needs to be validated prospectively.
Hirsch
Sheldon
S
Mercy Hospital and Michael Reese Hospital, Chicago, IL, USA. shelman100@aol.com
D000419:Albuminuria / Q000517:prevention & control; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006801:Humans; D006947:Hyperkalemia / Q000517:prevention & control; D006973:Hypertension / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control*; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D011507:Proteinuria / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control*; D012084:Renin-Angiotensin System / Q000187:drug effects
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D000451:Mineralocorticoid Receptor Antagonists